HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

defactinib

Also Known As:

N-methyl-4-((4-(((3-methyl(methylsulfonyl)aminopyrazin-2-yl)methyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzamide; PF-04554878; VS-6063

Networked: 34 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weaver, David T: 3 articles (01/2020 - 08/2017)
2.	Huang, Jian-An: 2 articles (12/2020 - 01/2020)
3.	Liu, Zeyi: 2 articles (12/2020 - 01/2020)
4.	Shi, Junfeng: 2 articles (12/2020 - 01/2020)
5.	Wei, Xiaowei: 2 articles (12/2020 - 01/2020)
6.	Wu, Yadi: 2 articles (12/2020 - 01/2020)
7.	Xu, Bingwei: 2 articles (12/2020 - 01/2020)
8.	Yang, Xiuwei H: 2 articles (12/2020 - 01/2020)
9.	Zhang, Yang: 2 articles (12/2020 - 01/2020)
10.	Keegan, Mitchell: 2 articles (01/2020 - 01/2016)

Related Diseases

1.	Neoplasms (Cancer) 08/08/2017 - "Prompted by our observation of a correlation between PTEN loss and FAK phosphorylation in a cohort of patients with stage IV SCC, we evaluated the relevance of PTEN loss in cancer progression as well as the efficacy of a new combined treatment with the pan PI3K inhibitor buparlisip and the FAK inhibitor defactinib. " 01/01/2016 - "These data support the administration of VS-6063 to Japanese subjects at the RP2D in clinical trials involving solid tumor malignancies." 01/01/2016 - "This phase 1 study evaluated the safety and tolerability, pharmacokinetics, and clinical activity of VS-6063 in Japanese subjects with advanced solid tumor malignancies in a first-in-Asian study setting. " 01/01/2023 - "defactinib) in cancer cells. " 01/01/2023 - "Last, the FAK inhibitor defactinib significantly suppresses the tumor growth of ccRCC with high p85β Y464 levels."
2.	Pancreatic Neoplasms (Pancreatic Cancer) 11/14/2023 - "Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study." 12/15/2022 - "Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study."
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/01/2022 - "Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial." 01/01/2020 - "Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer."
4.	Malignant Mesothelioma 01/01/2019 - "Questions Regarding the Randomized Phase II Trial of Defactinib as Maintenance Therapy in Malignant Pleural Mesothelioma." 01/01/2019 - "On this basis, we designed a randomized, phase II trial to investigate whether defactinib as maintenance therapy after standard first-line chemotherapy could improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM). "
5.	Mesothelioma 01/01/2019 - "Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study."

Related Drugs and Biologics

1.	Focal Adhesion Protein-Tyrosine Kinases
2.	Gemcitabine
3.	pembrolizumab
4.	Neurofibromin 2 (Merlin)
5.	defactinib
6.	PND 1186
7.	Small Interfering RNA (siRNA)
8.	Paclitaxel (Taxol)
9.	Cytokines
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Oral Administration